Basilea Pharmaceutica Ag Stock Short Ratio

BPMUF Stock  USD 52.83  0.00  0.00%   
Basilea Pharmaceutica AG fundamentals help investors to digest information that contributes to Basilea Pharmaceutica's financial success or failures. It also enables traders to predict the movement of Basilea Pink Sheet. The fundamental analysis module provides a way to measure Basilea Pharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Basilea Pharmaceutica pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Basilea Pharmaceutica AG Company Short Ratio Analysis

Basilea Pharmaceutica's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.

Short Ratio

 = 

Short Interest

Average Trading Volume

More About Short Ratio | All Equity Analysis
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
Competition

Based on the latest financial disclosure, Basilea Pharmaceutica AG has a Short Ratio of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The short ratio for all United States stocks is 100.0% higher than that of the company.

Basilea Short Ratio Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Basilea Pharmaceutica's direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Basilea Pharmaceutica could also be used in its relative valuation, which is a method of valuing Basilea Pharmaceutica by comparing valuation metrics of similar companies.
Basilea Pharmaceutica is currently under evaluation in short ratio category among its peers.

Basilea Fundamentals

About Basilea Pharmaceutica Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Basilea Pharmaceutica AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Basilea Pharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Basilea Pharmaceutica AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Basilea Pink Sheet

Basilea Pharmaceutica financial ratios help investors to determine whether Basilea Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Basilea with respect to the benefits of owning Basilea Pharmaceutica security.